Navigation Links
Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate

CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs." The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate.

"Our natriuretic compounds, including PL-3994, address significant unmet medical needs," said Trevor Hallam, Ph.D., Palatin's Executive Vice President - Research and Development. "These are the only reported compounds that bind to NPRA and have extended half-lives and pharmacokinetic properties making daily subcutaneous administration possible. Besides the potential to decrease re-hospitalization rates in patients with heart failure, PL-3994 may also have application in treating resistant hypertension and pulmonary arterial hypertension."

PL-3994 and the related family of cyclic compounds were discovered and developed by Palatin scientists and are solely owned by Palatin. In addition to this issued U.S. patent, Palatin has applications pending in selected countries outside the United States and additional U.S. applications covering related compounds.

About PL-3994

Palatin has completed two clinical trials with PL-3994, a Phase 1 trial in healthy volunteers and a Phase 2a trial in patients with controlled hypertension. PL-3994 produced dose-related decreases in blood pressure, increases in plasma cGMP (cyclic guanosine monophosphate), a natural messenger nucleotide, and increases in urine volume and sodium excretion. There were no serious or severe adverse events.

PL-3994 incorporates a novel and proprietary amino acid mimetic developed by scientists at Palatin. PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug candidate with improved pharmacokinetic and pharmacodynamic properties.

About Heart Failure

Heart failure affects over 5.7 million people in the United States, with 670,000 new cases diagnosed each year. Despite the treatment of heart failure with multiple drugs, the prognosis remains poor. There were over 1.1 million hospitalizations for heart failure in 2006 in the United States, with estimated direct and indirect costs of heart failure in the United States for 2009 of $37.2 billion.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to Palatin's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in the Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

SOURCE Palatin Technologies, Inc.

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
3. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
4. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
5. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
6. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
9. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
10. Palatin Technologies Receives Notification Letter from NYSE Alternext US
11. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
Post Your Comments:
(Date:11/30/2015)... Epigenetics Corp. ("Zenith" or the "Company") today announced that it ... Board of Directors to replace Dr. Peter Johann . ... as co-founder of Resverlogix, with expertise in the fields of ... --> Dr. Wong remarked, "I am very excited to ... expertise in epigenetics and the advanced stage of the R&D ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and Universal Partnerships ... opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the ... American tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one ...
(Date:11/30/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, ... Cypher Genomics, Inc., a leading genome informatics company offering ... solutions. The San Diego -based company ... CEO and Co-founder, Ashley Van Zeeland , Ph.D., who ... details of the deal were not disclosed. ...
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):